Detalhe da pesquisa
1.
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.
Proc Natl Acad Sci U S A
; 120(6): e2212072120, 2023 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724254
2.
Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
Mol Carcinog
; 63(6): 1024-1037, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38411275
3.
Histone H2AX promotes neuronal health by controlling mitochondrial homeostasis.
Proc Natl Acad Sci U S A
; 116(15): 7471-7476, 2019 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910969
4.
Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Cancer
; 124(3): 636-647, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29149451
5.
Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
Nucleic Acids Res
; 43(19): 9327-39, 2015 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26446994
6.
FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization.
World J Surg
; 40(3): 683-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26324161
7.
Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
Ann Surg Oncol
; 21(11): 3541-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24833102
8.
Histone H2AX promotes metastatic progression by preserving glycolysis via hexokinase-2.
Sci Rep
; 12(1): 3758, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35260660
9.
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
J Exp Clin Cancer Res
; 41(1): 282, 2022 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151566
10.
New Therapies for Advanced Thyroid Cancer.
Front Endocrinol (Lausanne)
; 11: 82, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32528402
11.
A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
Clin Cancer Res
; 26(8): 2022-2036, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31937621
12.
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835496
13.
Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
Thyroid
; 29(1): 79-92, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30398411
14.
Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.
Oncotarget
; 9(68): 33030-33042, 2018 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30250647
15.
68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.
Int J Endocr Oncol
; 5(1): IJE04, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30112163
16.
Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.
Clin Cancer Res
; 24(16): 4030-4043, 2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29691295
17.
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Clin Cancer Res
; 23(17): 5044-5054, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28600475
18.
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Oncotarget
; 7(13): 16517-28, 2016 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26934320
19.
MicroRNAs in the thyroid.
Best Pract Res Clin Endocrinol Metab
; 30(5): 603-619, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27923454
20.
LOX is a novel mitotic spindle-associated protein essential for mitosis.
Oncotarget
; 7(20): 29023-35, 2016 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27296552